VR Logo

Veracyte Inc. (VCYT) download report


Healthcare | Biotechnology & Pharma Research

Veracyte Inc. (VCYT) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery.

IPO Date: 30-Oct-2013

Co-Founder & Exec. Chairwoman: Ms. Bonnie H. Anderson

CEO & Director: Mr. Marc A. Stapley

Listing: NASDAQ: VCYT

Country: United States

Headquarters: South San Francisco, CA

Website: https://www.veracyte.com

Key Facts

Market cap: $1,426.76 Mln

Revenue (TTM): $250.59 Mln

Earnings (TTM): $-48.16 Mln

Cash: $163.62 Mln

Total Debt: $18.41 Mln

Insider's Holding: 0.74%

Liquidity: Low

52 Week range: $14.92 - 54.13

Shares outstanding: 71,445,296

10 Years Aggregate:

  • CFO: $-190.91 Mln
  • EBITDA: $-266.81 Mln
  • Net Profit: $-315.74 Mln

Stock Performance

Time Period Veracyte (VCYT) S&P BSE Sensex S&P Small-Cap 600
YTD-48.79-9.18-18.78
1 month11.70-4.78-8.00
3 months-23.47-9.66-13.65
1 Year-47.220.81-17.19
3 Years-9.5510.336.10
5 Years20.4311.345.87
10 Years--11.749.84
As on 01-Jul-2022
Year Veracyte (VCYT) S&P Small-Cap 600 S&P BSE Sensex
2021-15.8225.2721.99
202075.299.5715.75
2019121.9420.8614.38
201891.96-9.705.87
2017-15.6311.7327.91
20167.5024.741.95
2015-25.47-3.36-5.03